We are excited to welcome Engimmune Therapeutics as our newest portfolio company!
Engimmune Therapeutics is a platform and product development company using cutting-edge technologies in the life sciences to engineer highly potent and specific therapies based on T cell receptor (TCR) targeting of solid tumors. By applying functional high-throughput screening coupled with advanced computational methods, Engimmune addresses key efficacy and safety challenges that currently limit the full potential of TCR-T cell and soluble TCR therapeutics.
